The international team of scientists under the leadership of Professor Kiryaki Mikhailida from the Cyprus Institute of Neurology and Genetics published a study that significantly clarifying the risk of breast cancer and ovaries. The results based on the analysis of data of 400,000 women will help doctors more accurately interpret genetic tests and make clinical decisions.
The study published in the journal Nature Communications notes significant progress in the diagnosis and assessment of risks of breast cancer and ovaries, which allows more confidently interpreting mutations in the BRCA1 and BRCA2 genes.
Investigated mutations in genes
The International Group of Scientists, with the participation of the Biostatistics of the Cyprus Institute of Neurology and Genetics, analyzed data taken from 400,000 women from around the world to determine what genetic mutations in the BRCA1 and BRCA2 genes increase the risk of cancer. For many years it is known that these two genes have played an important role in a hereditary predisposition to some types of cancer. However, thousands of mutations in these genes remain an unexplored zone for doctors, since there are no exact data, how much they can affect the predisposition to cancer.
The team under the leadership of the Professor of the Cyprus Institute of Neurology and Genetics Kiryaki Mikhailida in cooperation with several scientific institutions from around the world has developed a statistical model that allows you to compare the frequency of specific mutations in women with cancer and without them. This allowed scientists to determine what genetic mutations are associated with an increased risk of oncology.
Not just the theory
“The results of the study are not just a theory, they can be applied in clinical practice. Doctors and genetics can now more accurately inform women undergoing genetic testing about whether they are carriers of dangerous mutations or not. This will allow women to make more informed decisions about their health, ”said Mikhailida.
The Cyprus Institute of Neurology and Genetics believe that a study conducted right now, when genetic testing is becoming more and more affordable, "will avoid unreasonable anxiety and not lose sight of real risks." The General Director of the Institute Leonidas Filakt noted that the results of the team "became another important step towards personalized medicine."
The article can be read here.
The text is prepared based on the materials of Cyprus mail
